318 related articles for article (PubMed ID: 19385713)
1. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Quinn DI; Nemunaitis J; Fuloria J; Britten CD; Gabrail N; Yee L; Acharya M; Chan K; Cohen N; Dudov A
Clin Pharmacokinet; 2009; 48(3):199-209. PubMed ID: 19385713
[TBL] [Abstract][Full Text] [Related]
2. Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
Hellmann A; Rule S; Walewski J; Shpilberg O; Feng H; van de Velde H; Patel H; Skee DM; Girgis S; Louw VJ
Clin Pharmacokinet; 2011 Dec; 50(12):781-91. PubMed ID: 22087865
[TBL] [Abstract][Full Text] [Related]
3. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
Venkatakrishnan K; Rader M; Ramanathan RK; Ramalingam S; Chen E; Riordan W; Trepicchio W; Cooper M; Karol M; von Moltke L; Neuwirth R; Egorin M; Chatta G
Clin Ther; 2009; 31 Pt 2():2444-58. PubMed ID: 20110052
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Moreau P; Karamanesht II; Domnikova N; Kyselyova MY; Vilchevska KV; Doronin VA; Schmidt A; Hulin C; Leleu X; Esseltine DL; Venkatakrishnan K; Skee D; Feng H; Girgis S; Cakana A; van de Velde H; Deraedt W; Facon T
Clin Pharmacokinet; 2012 Dec; 51(12):823-9. PubMed ID: 23018466
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Schwartz R; Davidson T
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib for the treatment of non-Hodgkin's lymphoma.
Bose P; Batalo MS; Holkova B; Grant S
Expert Opin Pharmacother; 2014 Nov; 15(16):2443-59. PubMed ID: 25263936
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
Reece DE; Sullivan D; Lonial S; Mohrbacher AF; Chatta G; Shustik C; Burris H; Venkatakrishnan K; Neuwirth R; Riordan WJ; Karol M; von Moltke LL; Acharya M; Zannikos P; Keith Stewart A
Cancer Chemother Pharmacol; 2011 Jan; 67(1):57-67. PubMed ID: 20306195
[TBL] [Abstract][Full Text] [Related]
8. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Ogawa Y; Tobinai K; Ogura M; Ando K; Tsuchiya T; Kobayashi Y; Watanabe T; Maruyama D; Morishima Y; Kagami Y; Taji H; Minami H; Itoh K; Nakata M; Hotta T
Cancer Sci; 2008 Jan; 99(1):140-4. PubMed ID: 17970782
[TBL] [Abstract][Full Text] [Related]
9. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
10. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
11. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of proton pump inhibitors in children.
Litalien C; Théorêt Y; Faure C
Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
[TBL] [Abstract][Full Text] [Related]
13. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
Fang AF; Damle BD; LaBadie RR; Crownover PH; Hewlett D; Glue PW
Pharmacotherapy; 2008 Jan; 28(1):42-50. PubMed ID: 18154473
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
Hamilton AL; Eder JP; Pavlick AC; Clark JW; Liebes L; Garcia-Carbonero R; Chachoua A; Ryan DP; Soma V; Farrell K; Kinchla N; Boyden J; Yee H; Zeleniuch-Jacquotte A; Wright J; Elliott P; Adams J; Muggia FM
J Clin Oncol; 2005 Sep; 23(25):6107-16. PubMed ID: 16135477
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
[TBL] [Abstract][Full Text] [Related]
16. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
17. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
18. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
[TBL] [Abstract][Full Text] [Related]
19. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
20. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
